Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Clinicopathological Characteristics of 11 NSCLC Patients with EGFR

Clinicopathological Characteristics of 11 NSCLC Patients with EGFR Anjana JTO BRIEF REPORT Exon 20 Mutations in NSCLC Clinicopathological Characteristics of 11 NSCLC Patients Lund-Iversen et al. with EGFR-Exon 20 Mutations Marius Lund-Iversen, MD,* Lilach Kleinberg, PhD,* Lars Fjellbirkeland, MD, PhD,†‡ Åslaug Helland, MD, PhD,‡§ and Odd Terje Brustugun, MD, PhD‡§ variable, with differences in both the natural course and in treat- Introduction: The characteristics of different types of epidermal ment effects. The presence of mutations in the kinase domain of growth factor receptor (EGFR) gene mutations in non–small-cell epidermal growth factor receptor (EGFR) gene has been regarded lung cancer (NSCLC) are not extensively studied. The distribution of as both a positive prognostic and predictive marker, and most EGFR mutations is known, with the most frequent in exon 19 (dele- EGFR mutation-positive patients respond well to tyrosine kinase tions) or exon 21 (point mutations). Aberrations in exon 18 or 20 1,2 inhibitors (TKIs) such as gefitinib or erlotinib. However, it is are infrequently found. Point mutations in exon 20 confer resistance now increasingly clear that not all EGFR mutations confer sen- against tyrosine kinase inhibitors (TKIs), whereas the effect of the sitivity to TKIs, and, especially, point mutations in exon 20 are rare exon 20 insertions is, to http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Clinicopathological Characteristics of 11 NSCLC Patients with EGFR

Journal of Thoracic Oncology , Volume 7 (9) – Sep 1, 2012

Loading next page...
 
/lp/wolters-kluwer-health/clinicopathological-characteristics-of-11-nsclc-patients-with-egfr-9wHu97ycGk

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Copyright
Copyright © 2012 by the International Association for the Study of Lung Cancer
ISSN
1556-0864
DOI
10.1097/JTO.0b013e3182614a9d
pmid
22895145
Publisher site
See Article on Publisher Site

Abstract

Anjana JTO BRIEF REPORT Exon 20 Mutations in NSCLC Clinicopathological Characteristics of 11 NSCLC Patients Lund-Iversen et al. with EGFR-Exon 20 Mutations Marius Lund-Iversen, MD,* Lilach Kleinberg, PhD,* Lars Fjellbirkeland, MD, PhD,†‡ Åslaug Helland, MD, PhD,‡§ and Odd Terje Brustugun, MD, PhD‡§ variable, with differences in both the natural course and in treat- Introduction: The characteristics of different types of epidermal ment effects. The presence of mutations in the kinase domain of growth factor receptor (EGFR) gene mutations in non–small-cell epidermal growth factor receptor (EGFR) gene has been regarded lung cancer (NSCLC) are not extensively studied. The distribution of as both a positive prognostic and predictive marker, and most EGFR mutations is known, with the most frequent in exon 19 (dele- EGFR mutation-positive patients respond well to tyrosine kinase tions) or exon 21 (point mutations). Aberrations in exon 18 or 20 1,2 inhibitors (TKIs) such as gefitinib or erlotinib. However, it is are infrequently found. Point mutations in exon 20 confer resistance now increasingly clear that not all EGFR mutations confer sen- against tyrosine kinase inhibitors (TKIs), whereas the effect of the sitivity to TKIs, and, especially, point mutations in exon 20 are rare exon 20 insertions is, to

Journal

Journal of Thoracic OncologyWolters Kluwer Health

Published: Sep 1, 2012

References